Eloxx Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ELOX | PRQR | TOVX | EXPRS2.ST | ATYR | ARCT | |
|---|---|---|---|---|---|---|
| Market cap | 51.42M | 198.98M | 8.72M | 38.52M | 15.45M | 308.96M |
| P/E (TTM) | 3.6 | — | 0.3 | — | — | — |
| Forward P/E | -17.9 | -3.0 | -1.0 | 0.0 | -0.3 | -2.9 |
| Price/book | 1.1 | 2.2 | 0.7 | 0.6 | 0.3 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +17.35% | −42.44% | −29.63% | −93.98% | −79.64% | +31.12% |
| Today | −1.39% | +2.92% | +4.40% | −2.40% | −6.79% | +13.94% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ELOX news ›Eloxx Pharmaceuticals (ELOXD) Projected to Announce Earnings on Tuesday
Posted by Danessa Lincoln on Nov 3rd, 2026 Eloxx Pharmaceuticals (OTCMKTS:ELOXD – Get Free Report) is expected to be releasing its resultson Tuesday, November 10th. Analysts expect Eloxx Pharmaceuticals to post earnings of ($0.5767) per…
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney... - First two patients dosed in the EXACT study - Topline data from the initial…
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
Fort Technology: Logia USA Signs Exclusive Distribution Agreement to Expand Fuel Maintenance Solutions for Data Centers Across the U.S. Zorronet Secures Initial Commercial Order for Its Edge AI Systems from a Leading Global Defense Company…
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
/PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney... - Mr. Germano brings more than 35 years of biopharmaceutical leadership…
Eloxx Pharmaceuticals Stock (ELOX): TheStreet Pro Articles, Analysis & Price Levels
Eloxx Pharmaceuticals Stock (ELOX) RealMoney Pro No articles mentioning ELOX yet. Upgrades: ArcelorMittal ($MT) upgraded to Overweight from Neutral at JPMorgan Array Technologies ($ARRY) upgraded to Outperform from Neutral at Mizuho,…
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% – Here’s What Happened
Posted by Defense World Staff on Oct 7th, 2026 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report)’s share price fell 5.2% during trading on Monday. The company traded as low as $1.72 and last traded at $1.7250. Approximately…
Orexo AB (publ) proposes SEK250M rights issue ahead of drug milestones
Orexo expects to announce final issue terms preliminarily on Nov. 3 and plans a shareholder vote for Nov. 6. An approximately SEK250 million rights issue would finance drug development and a possible U.S. Justice Department settlement…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com2
- stocktitan.net2
- defenseworld.net1
- mugglehead.com1
- pro.thestreet.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.